Compare MINISO Group Holding Ltd (MNSO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Organon & Co. Common Stock — how do they compare? MINISO Group Holding Ltd trades at $10.36 (market cap $2.89B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and MINISO Group Holding Ltd pays the higher dividend (6.71%). Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Organon & Co. Common Stock for 0 Days on average.
| MNSO | OGN | |
|---|---|---|
Market Cap | $2.89B | $3.62B |
Volume | 1,658,211 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $13.81 |
52-Week Low | $8.60 | $5.70 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $3.76B | $11.04B |
Dividend Yield | 6.71% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.92, up 1.95% with a bullish technical signal despite mixed earnings history. The company shows solid fundamentals with $21.44B revenue, 5.35% net margin, and attractive valuation ratios including P/E of 16.11 and P/S of 0.86. Recent CFO share purchases and analyst optimism (60% buy rating) support positive sentiment, though earnings misses in three of the last four quarters highlight execution risks amid competitive retail pressures.
The outlook remains cautiously optimistic given MNSO's valuation appeal and growth potential, but investors should monitor earnings consistency and overseas margin pressures. Key opportunities include domestic expansion and operational optimization, while risks involve volatile quarterly performance and intense retail competition.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
